Literature DB >> 14566972

JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.

Zhenggang Ren1, Siddhartha Kar, Ziqiu Wang, Meifang Wang, Joseph E Saavedra, Brian I Carr.   

Abstract

JS-K, a non-ionic diazeniumdiolate derivative, is capable of arylating nucleophiles and spontaneously generating nitric oxide (NO) at physiological pH. This recently synthesized low molecular weight compound is shown here to be an inhibitor of cell growth with concomitant activation of mitogen-activated protein kinase (MAPK) members ERK, JNK, and p38 and their downstream effectors c-Jun and AP-1. Inhibitors of these MAPK pathways abrogated the growth inhibitory actions of JS-K. In addition to the well-described actions of JNK as a kinase for c-Jun, we show that c-Jun is also an ERK target. Furthermore, JS-K generated NO in culture and NO inhibitors antagonized both MAPK induction and the growth inhibitory effects of JS-K. These results suggest two possible mechanisms for the mediation of JS-K growth inhibitory actions, namely NO-induction of MAPK pathway constituents as well as possible arylation reactions. The data support the idea that prolonged MAPK activation by JS-K action is important in mediating its growth-inhibitory actions. JS-K thus represents a promising platform for novel growth inhibitory analog synthesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566972     DOI: 10.1002/jcp.10380

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  28 in total

1.  JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.

Authors:  Vanity McMurtry; Joseph E Saavedra; René Nieves-Alicea; Ann-Marie Simeone; Larry K Keefer; Ana M Tari
Journal:  Int J Oncol       Date:  2011-01-25       Impact factor: 5.650

2.  Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

Authors:  Larry K Keefer
Journal:  For Immunopathol Dis Therap       Date:  2010-07-01

3.  Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.

Authors:  Anna E Maciag; Rahul S Nandurdikar; Sam Y Hong; Harinath Chakrapani; Bhalchandra Diwan; Nicole L Morris; Paul J Shami; Yih-Horng Shiao; Lucy M Anderson; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2011-10-28       Impact factor: 7.446

4.  Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Michael M Goodblatt; Vidya Udupi; Swati Malaviya; Paul J Shami; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

Review 5.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

6.  Exogenous NO induces apoptosis of hepatocellular carcinoma cells via positive p38/JNK signaling pathway and negative ERK signaling pathways.

Authors:  Ling Liu; Yihao Xing; Mengyao Cao; Jinglei Xu; Jingjing Chen
Journal:  Mol Cell Biochem       Date:  2021-01-09       Impact factor: 3.396

7.  Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Authors:  Varun Kumar; Sam Y Hong; Anna E Maciag; Joseph E Saavedra; Douglas H Adamson; Robert K Prud'homme; Larry K Keefer; Harinath Chakrapani
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

8.  Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.

Authors:  Monika Z Kaczmarek; Ryan J Holland; Stephen A Lavanier; Jami A Troxler; Valentyna I Fesenkova; Charlotte A Hanson; Joan L Cmarik; Joseph E Saavedra; Larry K Keefer; Sandra K Ruscetti
Journal:  Leuk Res       Date:  2013-12-12       Impact factor: 3.156

9.  Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Authors:  Daniela Andrei; Anna E Maciag; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

10.  Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin.

Authors:  Wei Xiong; Zheng-Gang Ren; Shuang-Jian Qiu; Hui-Chuan Sun; Lu Wang; Bin-Bin Liu; Qi-Song Li; Wei Zhang; Xiao-Dong Zhu; Liang Liu; Wen-Quan Wang; Zhao-You Tang
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.